The antifungal effectiveness of liquids used as intraocular tamponading agents in vitrectomy was tested against a strain of Aspergillus niger. This microorganism is a frequent causative factor of endophthalmitis. The strain belonged to the ATCC collection (A. niger ATCC 16404). The samples tested were: (a) perfluorocarbons: perfluorodecalin and perfluoroctane, (b) silicone oils: Siloil 1,000 and Siloil 5,000, and (c) balanced salt solutions: BSS and BSS Plus. The experiment consisted in inoculating the samples with the microorganism, in preserving the samples in 25°C in the dark, and in taking small amounts of each product for counting surviving microorganisms at t = 0 and then after 1 day, and 1, 2, 3 and 4 weeks. Among the samples tested, perfluorocarbons and silicone oils conform to the standards. No increase, and in some samples decrease, in the number of microorganisms is observed during the second week, while the number drops to zero at the end of the experiment. Therefore, the use of these liquids is safe.

1.
Spires R: Aspergillus-induced endophthalmitis. J Ophthalmic Nurs Technol 1995;14:124–126.
2.
Jager MJ, Chodosh J, Huang AJ, Alfonso EC, Culbertson WW, Forster RK: Aspergillus niger as an unusual cause of scleritis and endophthalmitis. Br J Ophthalmol 1994;78:584–586.
3.
Myles WM, Brownstein S, Deschenes J: Clinically unsuspected bilateral Aspergillus endophthalmitis. Can J Ophthalmol 1997;32:182–184.
4.
Boldrey EE: Bilateral endogenous Aspergillus endophthalmitis. Retina 1981;1:171–174.
5.
Krzystolik MG, Ciulla TA, Topping TM, Baker AS: Exogenous Aspergillus niger endophthalmitis in a patient with a filtering bleb. Retina 1997;17:461–462.
6.
Abu el-Asrar AM, al-Amro SA, al-Mosallam AA, al-Obeidan S: Post-traumatic endophthalmitis: Causative organisms and visual outcome. Eur J Ophthalmol 1999;9:21–31.
7.
Oxford KW, Abbott RL, Fung WE, Ellis DS: Aspergillus endophthalmitis after sutureless cataract surgery. Am J Ophthalmol 1995;120:534–535.
8.
Brar GS, Ram J, Kaushik S, Chakraborti A, Dogra MR, Gupta A: Aspergillus niger endophthalmitis after cataract surgery. J Cataract Refract Surg 2002;28:1882–1883.
9.
Narang S, Gupta A, Gupta V, Dogra MR, Ram J, Pandav SS, et al: Fungal endophthalmitis following cataract surgery: Clinical presentation, microbiological spectrum, and outcome. Am J Ophthalmol 2001;132:609–617.
10.
Valenton M: Wound infection after cataract surgery. Jpn J Ophthalmol 1996;40:447–455.
11.
Tabbara KF, al Jabarti AL: Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. Ophthalmology 1998;105:522–526.
12.
Brasseur G, Retout A, Charlin JF, Giron O, Tayot J: Endophthalmitis caused by Aspergillus (anatomo-clinical study of a case). Bull Soc Ophtalmol Fr 1989;89:305–306.
13.
Khurana AK, Mathur SK, Ahluwalia BK, Jain K, Sood S: An unusual case of endogenous aspergillus endophthalmitis. Acta Ophthalmol (Copenh) 1989;67:315–318.
14.
Sihota R, Agarwal HC, Grover AK, Sood NN: Aspergillus endophthalmitis. Br J Ophthalmol 1987;71:611–613.
15.
Feman SS, Nichols JC, Chung SM, Theobald TA: Endophthalmitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc 2002;100:67–71.
16.
Maalouf T, Schmitt C, Crance J, George J, Angioi K: Endogenous aspergillus endophthalmitis: A case report. J Fr Ophtalmol 2000;23:170–173.
17.
Weishaar PD, Flynn HW Jr, Murray TG, Davis JL, Barr CC, Gross JG, et al: Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes. Ophthalmology 1998;105:57–65.
18.
Valluri S, Moorthy RS, Liggett PE, Rao NA: Endogenous Aspergillus endophthalmitis in an immunocompetent individual. Int Ophthalmol 1993;17:131–135.
19.
Priddell Jv J, McNeil SA, Johnson TM, Bradley SF, Kazanjian PH, Kauffman CA: Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002;81:311–320.
20.
Wollensak G, Green WR: Remarkable case of early Aspergillus endophthalmitis. Aust N Z J Ophthalmol 1999;27:361–364.
21.
Gupta A, Gupta V, Dogra MR, Chakrabarti A, Ray P, Ram J, et al: Fungal endophthalmitis after a single intravenous administration of presumably contaminated dextrose infusion fluid. Retina 2000;20:262–268.
22.
Matsuo T, Nakagawa H, Matsuo N: Endogenous Aspergillus endophthalmitis associated with periodontitis. Ophthalmologica 1995;209:109–111.
23.
Doft BH, Clarkson JG, Rebell G, Forster RK: Endogenous Aspergillus endophthalmitis in drug abusers. Arch Ophthalmol 1980;98:859–862.
24.
Anteby I, Kramer M, Rahav G, Benezra D: Necrotizing choroiditis-retinitis as presenting symptom of disseminated aspergillosis after lung transplantation. Eur J Ophthalmol 1997;7:294–296.
25.
Cattelan AM, Loy M, Tognon S, Rea F, Sasset L, Cadrobbi P: An unusual presentation of invasive aspergillosis after lung transplantation. Transpl Int 2000;13:183–186.
26.
Graham DA, Kinyoun JL, George DP: Endogenous Aspergillus endophthalmitis after lung transplantation. Am J Ophthalmol 1995;119:107–109.
27.
Augsten R, Konigsdorffer E, Oehme A, Strobel J: Bilateral endogenous endophthalmitis. Klin Monatsbl Augenheilkd 1998;212:120–122.
28.
Coskuncan NM, Jabs DA, Dunn JP, Haller JA, Green WR, Vogelsang GB, et al: The eye in bone marrow transplantation. 6. Retinal complications. Arch Ophthalmol 1994;112:372–379.
29.
Hunt KE, Glasgow BJ: Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Ophthalmology 1996;103:757–767.
30.
Papanicolaou GA, Meyers BR, Fuchs WS, Guillory SL, Mendelson MH, Sheiner P, et al: Infectious ocular complications in orthotopic liver transplant patients. Clin Infect Dis 1997;24:1172–1177.
31.
Faschinger C, Faulborn J, Ganser K: Infectious corneal ulcers – once with endophthalmitis – after photorefractive keratotomy with disposable contact lens. Klin Monatsbl Augenheilkd 1995;206:96–102.
32.
Follows GA, Hutchinson C, Martin A, Carter C: Aspergillus fumigatus endophthalmitis in a patient with acute myeloid leukaemia. Clin Lab Haematol 1999;21:143–144.
33.
Hutnik CM, Nicolle DA, Munoz DG: Orbital aspergillosis. A fatal masquerader. J Neuroophthalmol 1997;17:257–261.
34.
Kronish JW, Johnson TE, Gilberg SM, Corrent GF, McLeish WM, Scott KR: Orbital infections in patients with human immunodeficiency virus infection. Ophthalmology 1996;103:1483–1492.
35.
Petersen M, Althaus C, Santen R, Gerharz CD: Endogenous Aspergillus endophthalmitis in AIDS. Klin Monatsbl Augenheilkd 1997;211:400–402.
36.
Bottoni F, Sborgia M, Arpa P, De Casa N, Bertazzi E, Monticelli M, et al: Perfluorocarbon liquids as postoperative short-term vitreous substitutes in complicated retinal detachment. Graefes Arch Clin Exp Ophthalmol 1993;231:619–628.
37.
Saxena S, Gopal L: Fluid vitreous substitutes in vitreo retinal surgery. Indian J Ophthalmol 1996;44:191–206.
38.
Kreiger AE, Lewis H: Management of giant retinal tears without scleral buckling. Use of radical dissection of the vitreous base and perfluoroctane and intraocular tamponade. Ophthalmology 1992;99:491–497.
39.
Sudhalkar HA, Johnson MW: Perfluorocarbon liquid manipulation of high-density intraocular foreign bodies. Retina 1998;18:460–465.
40.
Omulecki W, Nawrocki J, Sempinska-Szewczyk J: The use of perfluorocarbon liquid in the surgical removal of lenses luxated to the vitreous cavity. Klin Oczna 1998;100:207–209.
41.
Lewis H, Sanchez G: The use of perfluorocarbon liquids in the repositioning of posteriorly dislocated intraocular lenses. Ophthalmology 1993;100:1055–1059.
42.
Van Effenterre G, Le Mer Y, Lacotte JL, Ameline B: Posterior luxation of lens or implant: Surgical treatment using a perfluorocarbon solution. Technique and results of 13 cases. Fr Ophtalmol 1992;15:337–342.
43.
Yoshida K, Kiryu J, Kita M, Ogura Y: Phacoemulsification of dislocated lens and suture fixation of intraocular lens using a perfluorocarbon liquid. Jpn J Ophthalmol 1998;42:471–475.
44.
Itoh R, Ikeda T, Sawa H, Kolzumi K, Yasuhara T, Yamamoto Y, et al: The use of perfluorocarbon liquids in diabetic vitrectomy. Ophthalmic Surg Lasers 1999;30:672–675.
45.
Le Mer Y: Use of liquid perfluorocarbons in vitrectomy for difficult cases of proliferative diabetic retinopathy. J Fr Ophtalmol 1995;18:366–372.
46.
Eckardt C, Nicolai U, Winter M, Knop E: Experimental intraocular tolerance to liquid perfluoroctane and perfluoropolyether. Retina 1991;11:375–384.
47.
Weinberger D, Goldenberg-Cohen N, Axer-Siegel R, Gaton DD, Yassur Y: Long-term follow-up of perfluorocarbon liquid in the anterior chamber. Retina 1998;18:233–237.
48.
Stolba U, Krepler K, Velikay M, Binder S: Anterior segment changes in rabbits after experimental aqueous replacement with various amounts of different perfluorocarbon liquids. Graefes Arch Clin Exp Ophthalmol 1999;237:501–507.
49.
Malchiodi-Albedi F, Morgillo A, Formisano G, Paradisi S, Perilli R, Scalzo GC, et al: Biocompatibility assessment of silicone oil and perfluorocarbon liquids used in retinal reattachment surgery in rat retinal cultures. J Biomed Mater Res 2002;60:548–555.
50.
Bassat IB, Desatnik H, Alhalel A, Treister G, Moisseiev J: Reduced rate of retinal detachment following silicone oil removal. Retina 2000;20:597–603.
51.
Rao NA, Hidayat AA: Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am J Ophthalmol 2001;132:244–251.
52.
3e Rapport commun du Comité des Laboratoires et Services Officiels de Contrôle des Medicaments et de la Section des Pharmaciens de l’Industrie de la FIP: L’essai d’efficacité de la conservation antimicrobienne des preparations pharmaceutiques. Pharm Acta Helv 1979;54:370.
53.
Thurston AJ, McChesney A: The bacterial colonisation of silicone oil used in the management of wounds of the hands – A source of nosocomial infection? Hand Surg 2002;7:21–26.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.